The price of Nektar Therapeutics (NASDAQ: NKTR) closed at $0.91 in the last session, up 2.92% from day before closing price of $0.88. In other words, the price has increased by $+0.0258 from its previous closing price. On the day, 2518372 shares were traded.
Ratios:
We take a closer look at NKTR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.14 and its Current Ratio is at 6.45. In the meantime, Its Debt-to-Equity ratio is 1.76 whereas as Long-Term Debt/Eq ratio is at 1.61.
Jefferies Upgraded its Underperform to Hold on May 10, 2023, whereas the target price for the stock was revised from $1.50 to $1.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 20 ’24 when ROBIN HOWARD W sold 20,033 shares for $0.68 per share. The transaction valued at 13,622 led to the insider holds 879,889 shares of the business.
Zalevsky Jonathan sold 9,014 shares of NKTR for $6,130 on Feb 20 ’24. The Chief R&D Officer now owns 265,025 shares after completing the transaction at $0.68 per share. On Feb 20 ’24, another insider, Wilson Mark Andrew, who serves as the Chief Legal Officer of the company, sold 7,606 shares for $0.68 each. As a result, the insider received 5,172 and left with 236,674 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 165.26M and an Enterprise Value of -20.58M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.93 while its Price-to-Book (P/B) ratio in mrq is 1.33. Its current Enterprise Value per Revenue stands at -0.23 whereas that against EBITDA is 0.08.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.59, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 0.6116, while the 200-Day Moving Average is calculated to be 0.5892.
Shares Statistics:
According to the various share statistics, NKTR traded on average about 1.63M shares per day over the past 3-months and 3.96M shares per day over the past 10 days. A total of 191.38M shares are outstanding, with a floating share count of 188.09M. Insiders hold about 1.41% of the company’s shares, while institutions hold 62.62% stake in the company. Shares short for NKTR as of Feb 15, 2024 were 2.45M with a Short Ratio of 1.51, compared to 5.44M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.29% and a Short% of Float of 2.64%.
Earnings Estimates
The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.22, while EPS last year was -$0.73. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.09 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.34 and -$1.35 for the fiscal current year, implying an average EPS of -$0.81. EPS for the following year is -$0.66, with 5 analysts recommending between -$0.31 and -$1.08.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $93M, while the lowest revenue estimate was $22.2M, resulting in an average revenue estimate of $68.34M. In the same quarter a year ago, actual revenue was $90.12M, down -24.20% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $65.12M in the next fiscal year. The high estimate is $93M and the low estimate is $22.9M. The average revenue growth estimate for next year is down -4.70% from the average revenue estimate for this year.
